Publications by authors named "Kenneth Jarvis"

Claim this Profile
T
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Joann P Palma, Luis E Rodriguez, Velitchka D Bontcheva-Diaz, Jennifer J Bouska, Gail Bukofzer, Kenneth Jarvis

Anticancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies.
Wen-Zhen Gu, Ingrid Joseph, Yi-Chun Wang, David Frost, Gerard M Sullivan, Kenneth P Jarvis

Anticancer Drugs· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Debra Ferguson, Luis E Rodriguez, Joann P Palma, Marion Refici, Kenneth Jarvis

Clin Cancer Res· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis